4/24/2008

A federal report found that drugmakers, as of Sept. 30, had not begun 1,044 post-market drug studies that they pledged to the FDA they would perform. Promises for 444 of them date back to Oct. 1, 2004, or earlier. A spokeswoman for the FDA said it will make sure that drug firms finish the incomplete post-approval trials "in a timely manner."

Full Story:
Bloomberg1

Related Summaries